查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
止血劑市場：全球按類型、劑型、應用、最終用戶和地區分類 - 預測至 2030 年
市場調查報告書
商品編碼
1773177

止血劑市場：全球按類型、劑型、應用、最終用戶和地區分類 - 預測至 2030 年

Hemostats Market by Type (Thrombin, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, General, Cardiovascular), End User (Hospital, Specialty Clinic), Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 262 Pages | 訂單完成後即時交付

價格

全球止血劑市場預計將從 2025 年的 29 億美元成長到 2030 年的 40 億美元，預測期內的複合年成長率為 6.4%。

研究範圍
調查年份 2024-2030
基準年 2024
預測期 2024-2030
對價單位 金額（十億美元）
部分 按類型、劑型、用途、最終用戶和地區
目標區域 亞太地區、北美、歐洲、拉丁美洲、中東和非洲

老年人口的成長顯著增加了外科手術的需求，凸顯了止血劑在現代醫療保健中的重要角色。老年人更容易患上各種慢性疾病，這些疾病需要透過外科手術來恢復或改善功能。這包括整形外科關節重建以及更複雜的心血管和胃腸道手術。老齡化伴隨著生理變化，例如組織癒合能力下降和出血傾向增加。因此，合理使用止血劑對於最佳化老年人的外科手術效果至關重要。隨著全球老化速度的加快，預計止血劑的需求也將相應增加，凸顯了其在解決老年人複雜外科護理方面的重要性。然而，由於先進止血技術成本高且在資源匱乏的地區供應有限，其更廣泛地推廣可能面臨挑戰。

根據類型，止血劑市場細分為氧化再生纖維素止血劑、凝血酶止血劑、複合類止血劑、明膠類止血劑、膠原蛋白類止血劑和其他類止血劑。由於複合類止血劑的療效優於單一類止血劑，因此止血劑市場正在快速成長。這些先進的止血劑透過多種機制發揮作用，增強了其有效控制手術出血的能力。這些聯合治療的主要優點包括減少術中失血量、快速可靠的止血、縮短恢復時間、減少輸血頻率。此外，複合類止血劑的引入也改善了患者的預後，例如縮短了住院時間並加快了康復速度。

全球止血劑市場分為基質和凝膠止血劑、片狀和墊片止血劑、海綿止血劑和粉末止血劑。由於外科醫生和醫療保健專業人員越來越依賴海綿製劑，海綿止血劑市場成長最快。這些止血海綿吸收性強、使用方便，能很好地貼合不規則的傷口形狀，適用於各種外科手術。它們可促進快速止血，降低術後出血風險，並且通常以即用型出售，無需事先準備。此外，大多數海綿止血劑都是生物可吸收的，因此無需隨後移除，最大限度地減少了潛在的併發症。材料科學的最新趨勢導致了具有改進的生物相容性和抗菌性能的海綿止血劑的開發，進一步鞏固了其臨床偏好。這些創新不僅提高了安全性，也最佳化了各種手術情況下的療效。

止血劑市場按應用細分為整形外科、一般外科、神經外科、心血管外科、婦科外科、重組外科等。到 2024 年，整形外科將佔據止血劑市場的主導地位。這一趨勢歸因於與生活方式相關的疾病（如關節炎、骨質疏鬆症和肥胖症）的盛行率不斷上升，這些疾病往往會導致需要手術干預的肌肉骨骼併發症。人口結構向老齡化社會轉變，使人們更容易患上骨骼和關節退化性疾病，這也大大促進了整形外科手術需求的成長。此外，運動傷害和創傷性骨折發生率的上升導致需要進行更多的外科手術，而精準的止血管理至關重要。人們越來越偏好在不影響臨床結果的情況下優先考慮有效止血的微創整形外科手術，這進一步推動了市場需求。此外，新興市場醫療保健服務的改善和先進止血劑的供應正在推動這些產品在整形外科手術中的廣泛應用。

全球止血設備市場細分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。預計在預測期內，亞太地區的止血設備市場將顯著成長，主要得益於新興經濟體強勁的GDP成長和可支配收入的提高。這些經濟動態正在推動各領域的醫療保健支出成長。外科手術的激增、慢性病盛行率的上升以及醫療基礎設施的持續現代化，正在推動對止血設備等先進外科產品的需求。此外，先進醫療技術的日益整合及其向農村地區的傳播也在推動市場發展。醫療設施的快速擴張，尤其是中國和印度的醫院和診所，以及政府為提高疾病控制意識而採取的舉措，是這一成長的主要驅動力。此外，亞洲國家醫療保健支出的大幅成長正在提升醫療服務提供者的購買力，促進該地區採用創新止血設備。

本報告研究了全球止血劑市場，並對市場類型、劑型、應用、最終用戶、區域趨勢和公司概況進行了詳細分析。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章重要考察

第5章市場概述

  • 介紹
  • 市場動態
  • 產業趨勢
  • 技術分析
  • 定價分析
  • 生態系/市場地圖
  • 贖回方案
  • 價值鏈分析
  • 波特五力分析
  • 供應鏈分析
  • 貿易分析
  • 監管狀況
  • 專利分析
  • 大型會議及活動
  • 主要相關人員和採購標準
  • 鄰近市場分析
  • 影響客戶業務的趨勢/中斷
  • 未滿足的需求/最終用戶期望
  • 人工智慧（AI）對止血劑市場的影響
  • 案例研究分析
  • 投資金籌措場景
  • 美國關稅的影響-止血劑市場

第6章止血劑市場（按類型）

  • 介紹
  • 氧化再生纖維素止血劑
  • 凝血酶類止血劑
  • 複方止血劑
  • 明膠基止血劑
  • 膠原蛋白基止血劑
  • 其他

第7章止血劑市場（按劑型）

  • 介紹
  • 基質和凝膠止血劑
  • 止血床單和墊片
  • 海綿止血鉗
  • 粉狀止血劑

第8章止血劑市場（按應用）

  • 介紹
  • 整形外科
  • 一般外科
  • 神經外科
  • 心血管外科
  • 重組手術
  • 婦科手術
  • 其他

第9章止血劑市場（按最終用戶）

  • 介紹
  • 醫院
  • 專科診所
  • 其他

第 10 章止血劑市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 加強醫療基礎設施以支持市場成長
    • 中東和非洲宏觀經濟展望
    • 海灣合作理事會國家
    • 其他

第11章競爭格局

  • 介紹
  • 主要參與企業的策略/優勢
  • 收益分享分析
  • 市場佔有率分析
  • 公司估值矩陣：2024 年主要參與企業
  • 公司估值矩陣：Start-Ups/中小企業，2024 年
  • 估值和財務指標
  • 品牌/產品比較
  • 主要企業研發支出
  • 競爭場景

第12章 公司簡介

  • 主要參與企業
    • JOHNSON & JOHNSON SERVICES, INC.
    • BAXTER
    • PFIZER INC.
    • B. BRAUN SE
    • BECTON, DICKINSON AND COMPANY（BD）
    • TELEFLEX INCORPORATED
    • MEDTRONIC PLC
    • HEMOSTASIS, LLC
    • STRYKER
    • INTEGRA LIFESCIENCES
    • ADVANCED MEDICAL SOLUTIONS GROUP PLC
    • SAMYANG CORPORATION
  • 其他公司
    • MARINE POLYMER TECHNOLOGIES, INC.
    • GELITA MEDICAL
    • DILON TECHNOLOGIES
    • BETATECH MEDICAL
    • MERIL LIFE SCIENCES PVT. LTD.
    • BIOCER DEVELOPMENT GMBH
    • UNILENE
    • KATSAN MEDICAL DEVICES
    • TRICOL BIOMEDICAL
    • 3-D MATRIX MEDICAL TECHNOLOGY
    • HEMOSTAT MEDICAL GMBH
    • CELOX MEDICAL LTD.
    • ALTAYLAR MEDICAL

第13章 附錄

Product Code: MD 4093

The global hemostats market is projected to reach 4.0 billion in 2030 from USD 2.9 billion in 2025, at a CAGR of 6.4% during the forecast period."

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsType, Formulation, Application, End User, and Region
Regions coveredAsia Pacific, North America, Europe, Latin America, and Middle East & Africa

The escalating demographic of the elderly is driving a significant uptick in the demand for surgical interventions, highlighting the pivotal role of hemostatic agents within modern healthcare. As individuals age, they become more susceptible to a range of chronic conditions necessitating surgical correction to restore or improve functional capacity. This includes procedures such as orthopedic joint replacements and more complex cardiovascular and gastrointestinal surgeries. Aging is associated with physiological changes, including diminished tissue resilience and an elevated propensity for hemorrhage. Consequently, the judicious application of hemostatic agents is critical for optimizing surgical outcomes in geriatric patients. With the global aging population on the rise, the demand for hemostatic products is projected to escalate correspondingly, underscoring their essential contribution to addressing the intricate surgical care requirements of older adults. Nonetheless, the prohibitive costs of advanced hemostatic technologies coupled with limited accessibility in resource-constrained environments may pose challenges to their broader implementation.

"Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the study period."

The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The market for hemostatic agents is experiencing rapid growth due to the superior efficacy of combination hemostats compared to monotherapy products. These advanced hemostatic agents operate through multiple mechanisms, which enhance their ability to control surgical hemorrhage effectively. Key benefits associated with these combination products include decreased intraoperative blood loss, expedited and reliable hemostasis, reduced convalescence times, and a lower frequency of transfusion requirements. Furthermore, the implementation of combination hemostats has been linked to improved patient outcomes, such as shortened hospital stays and faster recovery trajectories.

"Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period."

The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is experiencing the most rapid growth due to an increasing reliance on sponge-based formulations among surgeons and healthcare professionals, attributed to several key advantages. These hemostatic sponges are highly absorbent, user-friendly, and conform well to irregular wound geometries, making them applicable to a wide range of surgical procedures. They facilitate prompt hemostasis, mitigate the risk of postoperative bleeding, and are frequently available in ready-to-use formats, eliminating the need for prior preparation. Furthermore, most sponge hemostats are bioresorbable, which removes the necessity for subsequent removal and minimizes potential complications. Recent advancements in material science have led to the development of sponge hemostats with enhanced biocompatibility and antimicrobial properties, further solidifying their clinical preference. These innovations not only improve the safety profile but also optimize their effectiveness in various surgical contexts.

"By application, the orthopedic surgery segment accounted for the largest share of the hemostats market in 2024."

The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. In 2024, the orthopedic surgery segment dominated the hemostats market, a trend driven by a rising prevalence of lifestyle-related conditions such as arthritis, osteoporosis, and obesity, which often lead to musculoskeletal complications requiring surgical intervention. The demographic shift towards an aging population, which is more susceptible to degenerative bone and joint disorders, also significantly contributes to the increased demand for orthopedic surgical procedures. Moreover, the escalating incidence of sports-related injuries and traumatic fractures necessitates a more substantial number of surgical interventions where precise hemostatic control is crucial. The growing preference for minimally invasive orthopedic techniques, which prioritize effective hemostasis without compromising clinical outcomes, further fuels market demand. Additionally, improved healthcare accessibility in emerging markets, coupled with the availability of advanced hemostatic agents, is facilitating the broader adoption of these products in orthopedic surgical practices.

"By region, the Asia Pacific was the fastest-growing region in the hemostats market in 2024."

The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is poised for significant growth in the hemostats market over the forecast period, primarily driven by robust GDP growth and rising disposable incomes in emerging economies. These economic dynamics are facilitating increased healthcare expenditure among broader demographics. The demand for sophisticated surgical products, such as hemostats, is escalating due to a surge in surgical procedures, a higher prevalence of chronic diseases, and the ongoing modernization of healthcare infrastructures. Moreover, the market is propelled by the increasing integration of advanced medical technologies, extending even into rural areas. The rapid expansion of healthcare facilities, particularly hospitals and clinics in China and India, combined with government initiatives to enhance disease management awareness, are critical contributors to this growth. Additionally, the significant uptick in healthcare spending across numerous Asian nations has bolstered the purchasing power of healthcare providers, thereby expediting the adoption of innovative hemostatic agents within the region.

The break-up of the profile of primary participants in the hemostats market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, Director-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

Prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey).

Research Coverage

The report analyzes the hemostats market, estimating the market size and potential for future growth across various segments, including end users, regions, applications, type, and formulation. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report provides valuable insights for market leaders and new entrants in the hemostats industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to position their businesses better and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, helping stakeholders gauge the current state of the market.

This report provides insights into the following pointers:

  • Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and increasing emphasis on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (increasing growth opportunities in emerging economies), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market.
  • Market Penetration: It provides detailed information on the product portfolios that major players in the global hemostats market offer. The report covers various segments: end user, region, application, type, and formulation.
  • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global hemostats market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the hemostats market across varied regions.
  • Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global hemostats market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global hemostats market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 INCLUSIONS AND EXCLUSIONS
    • 1.3.2 MARKETS COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 UNIT CONSIDERED
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 SCOPE-RELATED LIMITATIONS
    • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMOSTATS MARKET
  • 4.2 ASIA PACIFIC HEMOSTATS MARKET, BY END USER AND COUNTRY
  • 4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 REGIONAL MIX: HEMOSTATS MARKET (2023-2030)
  • 4.5 HEMOSTATS MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2025 VS. 2030 (USD MILLION)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing volume of surgical procedures performed
      • 5.2.1.2 Increasing focus on R&D
      • 5.2.1.3 Rising focus on effective blood loss management in patients during surgeries
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Side effects and allergic reactions associated with hemostats
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential in emerging economies
      • 5.2.3.2 Growing number of hospitals
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory requirements for hemostat products
      • 5.2.4.2 Lack of skilled personnel for effective use of hemostats
      • 5.2.4.3 High cost of hemostats
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 INCREASED POPULARITY OF COMBINATION HEMOSTATS
    • 5.3.2 CONSOLIDATION OF HOSPITALS
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Passive hemostats
      • 5.4.1.2 Chitosan-based hemostats
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Surgical adhesives
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Drug-eluting sutures for local therapeutic delivery
      • 5.4.3.2 Barbed sutures
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY HEMOSTAT
    • 5.5.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022-2024 (USD)
  • 5.6 ECOSYSTEM/MARKET MAP
  • 5.7 REIMBURSEMENT SCENARIO
  • 5.8 VALUE CHAIN ANALYSIS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 SUPPLY CHAIN ANALYSIS
  • 5.11 TRADE ANALYSIS
    • 5.11.1 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020-2024
    • 5.11.2 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020-2024
  • 5.12 REGULATORY LANDSCAPE
    • 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.12.2 REGULATORY FRAMEWORK
      • 5.12.2.1 North America
        • 5.12.2.1.1 US
        • 5.12.2.1.2 Canada
      • 5.12.2.2 Europe
      • 5.12.2.3 Asia Pacific
        • 5.12.2.3.1 Japan
        • 5.12.2.3.2 China
        • 5.12.2.3.3 India
  • 5.13 PATENT ANALYSIS
    • 5.13.1 PATENT PUBLICATION TRENDS FOR HEMOSTATS MARKET
    • 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN HEMOSTATS MARKET
  • 5.14 KEY CONFERENCES & EVENTS
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.2 KEY BUYING CRITERIA
  • 5.16 ADJACENT MARKET ANALYSIS
  • 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.18 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.19 IMPACT OF ARTIFICIAL INTELLIGENCE (AI) ON HEMOSTATS MARKET
  • 5.20 CASE STUDY ANALYSIS
    • 5.20.1 EGYPT'S INCURA LEVERAGES MACHINE LEARNING TO REINVENT TRAUMA HEMOSTASIS
    • 5.20.2 SOLE-SUPPLIER TRANSITION FOR HEMOSTATIC AGENTS AT OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
  • 5.21 INVESTMENT AND FUNDING SCENARIO
  • 5.22 IMPACT OF US TARIFF - HEMOSTATS MARKET
    • 5.22.1 INTRODUCTION
    • 5.22.2 KEY TARIFF RATES
    • 5.22.3 PRICE IMPACT ANALYSIS
    • 5.22.4 IMPACT ON REGION
      • 5.22.4.1 US
      • 5.22.4.2 Europe
      • 5.22.4.3 Asia Pacific
    • 5.22.5 IMPACT ON END-USE INDUSTRIES

6 HEMOSTATS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
    • 6.2.1 HIGH BIOCOMPATIBILITY TO DRIVE ITS ADOPTION
  • 6.3 THROMBIN-BASED HEMOSTATS
    • 6.3.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
  • 6.4 COMBINATION HEMOSTATS
    • 6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS TO DRIVE MARKET
  • 6.5 GELATIN-BASED HEMOSTATS
    • 6.5.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
  • 6.6 COLLAGEN-BASED HEMOSTATS
    • 6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
  • 6.7 OTHER HEMOSTATS

7 HEMOSTATS MARKET, BY FORMULATION

  • 7.1 INTRODUCTION
  • 7.2 MATRIX & GEL HEMOSTATS
    • 7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
  • 7.3 SHEET & PAD HEMOSTATS
    • 7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
  • 7.4 SPONGE HEMOSTATS
    • 7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO DRIVE DEMAND
  • 7.5 POWDER HEMOSTATS
    • 7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO DRIVE DEMAND

8 HEMOSTATS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 ORTHOPEDIC SURGERY
    • 8.2.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
  • 8.3 GENERAL SURGERY
    • 8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
  • 8.4 NEUROLOGICAL SURGERY
    • 8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET
  • 8.5 CARDIOVASCULAR SURGERY
    • 8.5.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
  • 8.6 RECONSTRUCTIVE SURGERY
    • 8.6.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
  • 8.7 GYNECOLOGICAL SURGERY
    • 8.7.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
  • 8.8 OTHER SURGICAL APPLICATIONS

9 HEMOSTATS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 GROWING ADOPTION OF MINIMALLY INVASIVE SURGERIES TO BOOST ADOPTION OF HEMOSTATS
  • 9.3 SPECIALTY CLINICS
    • 9.3.1 EXPANDING SPECIALTY CLINICS TO PROMOTE MARKET GROWTH
  • 9.4 OTHERS

10 HEMOSTATS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Strong healthcare infrastructure to support uptake of hemostats
    • 10.2.3 CANADA
      • 10.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 High healthcare expenditure in Germany to drive market
    • 10.3.3 UK
      • 10.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market
    • 10.3.4 FRANCE
      • 10.3.4.1 Presence of well-established healthcare system to drive market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing volume of surgeries to drive demand for hemostats
    • 10.3.6 SPAIN
      • 10.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth
    • 10.4.3 JAPAN
      • 10.4.3.1 Strong healthcare system and rising geriatric population to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Rising healthcare awareness and favorable government support to drive market
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Well-established healthcare infrastructure to drive adoption of hemostats
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Brazil to dominate Latin American market for hemostats
    • 10.5.3 MEXICO
      • 10.5.3.1 Low-cost surgeries to drive medical tourism in Mexico
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.3 GCC COUNTRIES
    • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
  • 11.3 REVENUE SHARE ANALYSIS
  • 11.4 MARKET SHARE ANALYSIS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Type footprint
      • 11.5.5.4 Formulation footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 11.6.5.1 Detailed list of key startups/SMEs
      • 11.6.5.2 Competitive benchmarking of key startups/SMEs
  • 11.7 VALUATION & FINANCIAL METRICS
    • 11.7.1 FINANCIAL METRICS
    • 11.7.2 COMPANY VALUATION
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 R&D EXPENDITURE OF KEY PLAYERS
  • 11.10 COMPETITIVE SCENARIO
    • 11.10.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.10.2 DEALS
    • 11.10.3 EXPANSIONS
    • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 JOHNSON & JOHNSON SERVICES, INC.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product approvals & launches
        • 12.1.1.3.2 Deals
        • 12.1.1.3.3 Other developments
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 BAXTER
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product approvals & launches
        • 12.1.2.3.2 Other developments
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 PFIZER INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 B. BRAUN SE
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Right to win
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 BECTON, DICKINSON AND COMPANY (BD)
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Other developments
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Right to win
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 TELEFLEX INCORPORATED
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product approvals & launches
        • 12.1.6.3.2 Deals
        • 12.1.6.3.3 Other developments
    • 12.1.7 MEDTRONIC PLC
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Product approvals & launches
        • 12.1.7.3.2 Expansions
    • 12.1.8 HEMOSTASIS, LLC
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Deals
    • 12.1.9 STRYKER
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Expansions
    • 12.1.10 INTEGRA LIFESCIENCES
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
    • 12.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Deals
    • 12.1.12 SAMYANG CORPORATION
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 MARINE POLYMER TECHNOLOGIES, INC.
    • 12.2.2 GELITA MEDICAL
    • 12.2.3 DILON TECHNOLOGIES
    • 12.2.4 BETATECH MEDICAL
    • 12.2.5 MERIL LIFE SCIENCES PVT. LTD.
    • 12.2.6 BIOCER DEVELOPMENT GMBH
    • 12.2.7 UNILENE
    • 12.2.8 KATSAN MEDICAL DEVICES
    • 12.2.9 TRICOL BIOMEDICAL
    • 12.2.10 3-D MATRIX MEDICAL TECHNOLOGY
    • 12.2.11 HEMOSTAT MEDICAL GMBH
    • 12.2.12 CELOX MEDICAL LTD.
    • 12.2.13 ALTAYLAR MEDICAL

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORT
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • TABLE 2 RESEARCH ASSUMPTIONS
  • TABLE 3 RISK ASSESSMENT
  • TABLE 4 GERIATRIC POPULATION, BY REGION, 2016 VS. 2023
  • TABLE 5 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021
  • TABLE 6 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021
  • TABLE 7 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
  • TABLE 8 INDICATIVE PRICING FOR HEMOSTATS
  • TABLE 9 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022-2024 (USD)
  • TABLE 10 ROLE IN ECOSYSTEM: HEMOSTATS MARKET
  • TABLE 11 HEMOSTATS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 12 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 13 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
  • TABLE 20 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN
  • TABLE 21 NMPA MEDICAL DEVICES CLASSIFICATION
  • TABLE 22 LIST OF MAJOR PATENTS IN HEMOSTATS MARKET 2022-2024
  • TABLE 23 HEMOSTATS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS
  • TABLE 25 KEY BUYING CRITERIA FOR END USERS
  • TABLE 26 HEMOSTATS MARKET: UNMET NEEDS
  • TABLE 27 HEMOSTATS MARKET: END-USER EXPECTATIONS
  • TABLE 28 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 29 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR HEMOSTATS
  • TABLE 30 HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 31 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET
  • TABLE 32 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET
  • TABLE 34 THROMBIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET
  • TABLE 36 COMBINATION HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET
  • TABLE 38 GELATIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET
  • TABLE 40 COLLAGEN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 OTHER HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 43 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 45 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 47 SPONGE HEMOSTATS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 48 SPONGE HEMOSTATS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 49 POWDER HEMOSTATS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 POWDER HEMOSTATS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 51 HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 52 NUMBER OF KNEE & HIP REPLACEMENTS, 2021
  • TABLE 53 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021
  • TABLE 55 HEMOSTATS MARKET FOR GENERAL SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 62 HEMOSTATS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 HEMOSTATS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 HEMOSTATS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 HEMOSTATS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 71 US: KEY MACROINDICATORS
  • TABLE 72 US: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 73 US: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 74 US: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 75 US: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 76 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021
  • TABLE 77 CANADA: KEY MACROINDICATORS
  • TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 79 CANADA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 80 CANADA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 81 CANADA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 82 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 EUROPE: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 86 EUROPE: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021
  • TABLE 88 GERMANY: KEY MACROINDICATORS
  • TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 90 GERMANY: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 91 GERMANY: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 92 GERMANY: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 93 SURGICAL PROCEDURES PERFORMED IN UK, 2021
  • TABLE 94 UK: KEY MACROINDICATORS
  • TABLE 95 UK: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 96 UK: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 97 UK: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 98 UK: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 99 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021
  • TABLE 100 FRANCE: KEY MACROINDICATORS
  • TABLE 101 FRANCE: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 102 FRANCE: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 103 FRANCE: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 104 FRANCE: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 105 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021
  • TABLE 106 ITALY: KEY MACROINDICATORS
  • TABLE 107 ITALY: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 108 ITALY: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 109 ITALY: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 110 ITALY: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 111 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021
  • TABLE 112 SPAIN: KEY MACROINDICATORS
  • TABLE 113 SPAIN: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 114 SPAIN: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 115 SPAIN: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 116 SPAIN: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 117 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
  • TABLE 118 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 119 REST OF EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 120 REST OF EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 121 REST OF EUROPE: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 128 CHINA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 129 CHINA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 130 CHINA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 131 JAPAN: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 132 JAPAN: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 133 JAPAN: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 134 JAPAN: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 135 INDIA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 INDIA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 137 INDIA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 138 INDIA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 139 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 140 AUSTRALIA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 141 AUSTRALIA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 142 AUSTRALIA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 143 SURGICAL PROCEDURES IN SOUTH KOREA, 2021
  • TABLE 144 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 145 SOUTH KOREA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 146 SOUTH KOREA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 147 SOUTH KOREA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 155 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 157 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 158 BRAZIL: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 159 BRAZIL: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 160 BRAZIL: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 161 MEXICO: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 162 MEXICO: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 163 MEXICO: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 164 MEXICO: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 165 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 167 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 168 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 172 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 176 GCC COUNTRIES: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 179 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 181 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 182 STRATEGIES ADOPTED BY KEY PLAYERS IN HEMOSTATS MARKET, JANUARY 2022-MAY 2025
  • TABLE 183 HEMOSTATS MARKET: DEGREE OF COMPETITION
  • TABLE 184 HEMOSTATS MARKET: REGION FOOTPRINT
  • TABLE 185 HEMOSTATS MARKET: TYPE FOOTPRINT
  • TABLE 186 HEMOSTATS MARKET: FORMULATION FOOTPRINT
  • TABLE 187 HEMOSTATS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 188 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 189 HEMOSTATS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 190 HEMOSTATS MARKET: DEALS, JANUARY 2022-MAY 2025
  • TABLE 191 HEMOSTATS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 192 HEMOSTATS MARKET: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 193 JOHNSON & JOHNSON: COMPANY OVERVIEW
  • TABLE 194 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 195 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 196 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 197 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 198 BAXTER: COMPANY OVERVIEW
  • TABLE 199 BAXTER: PRODUCTS OFFERED
  • TABLE 200 BAXTER: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 201 BAXTER: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 202 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 203 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 204 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 205 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 206 BD: COMPANY OVERVIEW
  • TABLE 207 BD: PRODUCTS OFFERED
  • TABLE 208 BD: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 209 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 210 TELEFLEX INCORPORATED: PRODUCTS OFFERED
  • TABLE 211 TELEFLEX INCORPORATED: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 212 TELEFLEX INCORPORATED: DEALS, JANUARY 2022-MAY 2025
  • TABLE 213 TELEFLEX INCORPORATED: OTHER DEVELOPMENTS, JANUARY 2022-MAY 2025
  • TABLE 214 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 215 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 216 MEDTRONIC: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022-MAY 2025
  • TABLE 217 MEDTRONIC: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 218 HEMOSTASIS, LLC: COMPANY OVERVIEW
  • TABLE 219 HEMOSTASIS, LLC: PRODUCTS OFFERED
  • TABLE 220 HEMOSTASIS, LLC: DEALS, JANUARY 2022-MAY 2025
  • TABLE 221 STRYKER: COMPANY OVERVIEW
  • TABLE 222 STRYKER: PRODUCTS OFFERED
  • TABLE 223 STRYKER: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 224 INTEGRA LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 225 INTEGRA LIFESCIENCES: PRODUCTS OFFERED
  • TABLE 226 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW
  • TABLE 227 ADVANCED MEDICAL SOLUTIONS GROUP PLC: PRODUCTS OFFERED
  • TABLE 228 ADVANCED MEDICAL SOLUTIONS GROUP PLC: DEALS, JANUARY 2022-MAY 2025
  • TABLE 229 SAMYANG CORPORATION: COMPANY OVERVIEW
  • TABLE 230 SAMYANG CORPORATION: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 6 REVENUE SHARE ANALYSIS FOR JHONSON & JOHNSON SERVICES, INC. (US) (2024)
  • FIGURE 7 HEMOSTATS MARKET: SUPPLY SIDE ANALYSIS (2024)
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2025-2030)
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 HEMOSTATS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 HEMOSTATS MARKET, BY FORMULATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 HEMOSTATS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 HEMOSTATS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 HEMOSTATS MARKET: REGIONAL SNAPSHOT
  • FIGURE 17 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
  • FIGURE 18 CHINA TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC
  • FIGURE 19 INDIA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 20 NORTH AMERICA TO DOMINATE HEMOSTATS MARKET DURING FORECAST PERIOD
  • FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGH GROWTH DURING FORECAST PERIOD
  • FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN HEMOSTATS MARKET
  • FIGURE 23 HEMOSTATS MARKET: ROLE IN ECOSYSTEM, 2024
  • FIGURE 24 HEMOSTATS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 PORTER'S FIVE FORCES ANALYSIS: HEMOSTATS MARKET
  • FIGURE 26 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
  • FIGURE 28 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
  • FIGURE 29 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
  • FIGURE 30 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR HEMOSTATS MARKET (JANUARY 2014-DECEMBER 2024)
  • FIGURE 31 TOP PATENT APPLICANT COUNTRIES FOR HEMOSTATS MARKET (JANUARY 2014-DECEMBER 2024)
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS
  • FIGURE 33 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 34 HEMOSTATS MARKET: ADJACENT MARKETS
  • FIGURE 35 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 36 INVESTMENT/VENTURE CAPITAL SCENARIO IN HEMOSTATS MARKET, 2022-2024
  • FIGURE 37 HEMOSTATS MARKET: GEOGRAPHIC SNAPSHOT (2025-2030)
  • FIGURE 38 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 39 EUROPE: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 40 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 41 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2022-2024
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HEMOSTATS MARKET (2024)
  • FIGURE 43 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 44 HEMOSTATS MARKET: COMPANY FOOTPRINT
  • FIGURE 45 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 46 EV/EBITDA OF KEY VENDORS
  • FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 48 HEMOSTATS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN HEMOSTATS MARKET, 2022-2024
  • FIGURE 50 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BAXTER: COMPANY SNAPSHOT (2024)
  • FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 B. BRAUN SE: COMPANY SNAPSHOT: (2024)
  • FIGURE 54 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 55 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2024)
  • FIGURE 56 MEDTRONIC: COMPANY SNAPSHOT (2024)
  • FIGURE 57 STRYKER: COMPANY SNAPSHOT (2024)
  • FIGURE 58 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2024)
  • FIGURE 59 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 60 SAMYANG CORPORATION: COMPANY SNAPSHOT (2024)